Logo

Genmab Achieves Milestone in Collaboration with Roche

Oct 27, 2003

NEW YORK, Oct. 27 (GenomeWeb News) - Genmab has reached a second milestone in its ongoing antibody development collaboration with Roche, having reached the proof of concept stage with a human antibody, the companies said today.

 

The size of the milestone was not disclosed.


The partnership was formed in May 2001, and calls for Genmab to create human antibodies against a variety of disease targets provided by Roche. Genmab stands to receive up to $100 million in milestones, as well as royalties on sales of products resulting from the deal. Genmab may also obtain the right to develop certain products based on disease targets identified by Roche.

 

The companies said that they now have moved two antibodies into the proof of concept stage of development.

Breaking News
The Scan

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.

TB Resistance Insights Gleaned From Genome Sequence, Antimicrobial Response Assays

Researchers in PLOS Biology explore M. tuberculosis resistance with a combination of sequencing and assays looking at the minimum inhibitory concentrations of 13 drugs.

Mendelian Disease Genes Prioritized Using Tissue-Specific Expression Clues

Mendelian gene candidates could be flagged for further functional analyses based on tissue-specific transcriptome and proteome profiles, a new Journal of Human Genetics paper says.

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.